Armata Pharmaceuticals Inc
TG1N
Company Profile
Business description
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Contact
5005 McConnell Avenue
Los AngelesCA90066
USAT: +1 310 665-2928
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
75
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,504.80 | 37.80 | 0.45% |
| CAC 40 | 7,850.10 | 106.35 | 1.37% |
| DAX 40 | 23,566.54 | 67.22 | 0.29% |
| Dow JONES (US) | 42,410.10 | 1,160.72 | 2.81% |
| FTSE 100 | 8,604.98 | 50.18 | 0.59% |
| HKSE | 23,230.86 | 318.60 | -1.35% |
| NASDAQ | 18,708.34 | 779.43 | 4.35% |
| Nikkei 225 | 38,282.28 | 638.02 | 1.69% |
| NZX 50 Index | 12,786.74 | 109.99 | 0.87% |
| S&P 500 | 5,844.19 | 184.28 | 3.26% |
| S&P/ASX 200 | 8,263.20 | 29.70 | 0.36% |
| SSE Composite Index | 3,376.08 | 6.84 | 0.20% |